Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support
Condition: Progesterone
Study type: Interventional

Summary: 
      The invesigators aimed to seperate the patients,which is going to be applied IUI, to two
      different groups as prospective randomized controlled ;assess the efficacy of the two
      different way pressurised progesterone by appling intravaginal progesterone to the first
      group; subcutaneous to the second group.
    

Detailed description: 
      Approxymately %10-15 of the couples who are in reproductive age ,have infertility issues.
      %30-40 male factor ,%40-50 female factor and %20-25 both factors play a role in infertility
      etiology. Contributory factors of cases are %30-40 male factors, %40-50 female factors and
      %20-25 mixed type. Ovulation induction and intrauterine insemination(IUI) are the main
      treatments in infertility.IUI is accepted as the most used treatment procedure according to
      other assisted reproductive techniques because it has lower costs ,can be easy applied and
      less invasive.Luteal phase ,which is approximately 14 days,is identified as between the time
      of ovulation and the beginning of the menstruation period. The production of progesterone in
      this period,is related to the function of corpus luteum. Progesterone is used as luteal
      support in patients which are applied ovulation induction with gonadotropin(GND).
      Gonadotropin is going to be used for controlled ovarian stimulation. The treatment is going
      to be started on second or third day of the cycle and GND dose is going to be determined
      according to the patient's age, body mass index, ovary reserve and past stimulation dose
      answer. Treatment processed gonadotropin dose is going to be arranged according to the
      follicle's progress and endometrial thickness. Human chorionic gonadotropin(hCG) is going to
      be added to the treatment when dominant follicle's diameter reached to 17-18mm for occuring
      of the ovulation. Sperm obtained by density gradient method using fresh sperm 36 hours after
      hCG, is going to be applied to the female partner with the help of a soft catheter in the
      dorsalitotomy position under ultrasound guidance. The patient is going to be kept in the
      supine position after the procedure for 15 minutes. Each patient is going to be given a
      single insemination and told to resume sexual intercourse for 3 days after the procedure.
      Intravaginal progesterone once a day to the first group after insemination to the patients
      divided into two different groups with randomized controlled (LUTINUS® 100 mg vaginal tablet,
      Ferring GmbH Wittland/Kiel/Germany) , second group subcutaneous progesterone (PROLUTEX® 25 mg
      Solution for injection, IBSA Group, Lugano, Switzerland) is going to be used once a day.
      Clinical pregnancy rates are going to be recorded by performing a blood pregnancy test on the
      15th day after the procedure. The investigators aimed to separate the patients, who are going
      to be applied IUI, in to two different groups as prospective randomized controlled; assess
      the efficacy of the two different way applied progesterone by appling intravaginal
      progesterone to the first group; subcutaneous to the second group.
    

Intervention name(s): subcutaneous progesterone; vaginal progesterone
Intervention type(s): Drug; Drug
Intervention description(s): clinical pregnancy rates; clinical pregnancy rates
Intervention MeSH terms: Progesterone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: progesterone; iui